Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
December 14th 2017

Q&A With Dr Thomas LeBlanc: The Value of ePROs in Oncology

Surabhi Dangi-Garimella, PhD
The FDA has recognized the need to include the patient's voice in the drug development process. The question is: what is the best way to do this?
FDA Announces Public Education Campaign to Encourage Smoking Cessation
December 14th 2017

FDA Announces Public Education Campaign to Encourage Smoking Cessation

Jaime Rosenberg
The FDA has announced its launch of the “Every Try Counts” campaign, which will encourage smokers to quit by advertising messages of support underscoring the health benefits of quitting. The campaign will also focus on celebrating each quit attempt as a step towards success.
Site Logo
December 13th 2017

Halt and Catch Fire: Can the Digital Revolution Empower the Move Toward Value-Based Cancer Care?

Joseph Alvarnas, MD
There is no shortage of academic, industry, and government sources that identify value as equaling cost/outcomes; there is far less uniformity of opinion when it comes to defining what that means for a particular patient affected by cancer.
Site Logo
December 13th 2017

How Technology, Social Media Are Changing the Way Clinical Trials Connect With Patients

Mary Caffrey
New companies are finding patients for clinical trials in remote locations and trimming months off the enrollment process.
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 13th 2017

Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma

Stephen Schuster, MD, of the Perelman School of Medicine, provides a summary of results seen with CAR T treatments in leukemia, lymphoma, and myeloma.
Site Logo
December 13th 2017

New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study

Surabhi Dangi-Garimella, PhD
Including the modified brentuximab antibody in the treatment regimen improved modified progression-free survival by 5%, although the rates of neutropenia and infections were higher in patients administered the brentuximab-containing regimen.
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12th 2017

Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children

Adolescents and young adults with acute lymphoblastic leukemia (ALL) tend to have worse outcomes than children with ALL, and new research published at the 59th American Society of Hematology Annual Meeting delved into the reasons why, explained Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.
Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures
December 12th 2017

Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures

Right now is a critical time for the healthcare industry to evaluate how patients are financially burdened by novel treatments that can provide tremendous outcomes, said Joshua R. Richter, MD, of the John Theurer Cancer Center.
Site Logo
December 12th 2017

EHR Documentation and the Patient–Physician Visit

Sheree Starrett, MD, MS
The need for physicicans to gather information for electronic health records has changed the nature of the patient visit.
Site Logo
December 12th 2017

CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients

Surabhi Dangi-Garimella, PhD
A much-anticipated session on the second day of the 59th Annual Meeting and Exposition of the American Society of Hematology provided long-term updates on trials evaluating 2 chimeric antigen receptor-T (CAR T) treatments: tisagenlecleucel or CTL019 (Kymriah) for the treatment of adult relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and axicabtagene ciloleucel (Yescarta) evaluated in patients with refractory aggressive non-Hodgkin lymphoma.
Racial Disparities Prevalent in Survival of Patients With Ovarian, Colon, and Breast Cancer
December 12th 2017

Racial Disparities Prevalent in Survival of Patients With Ovarian, Colon, and Breast Cancer

Jaime Rosenberg
Findings from 3 analyses published in CANCER highlight racial disparities in the survival of patients with ovarian, colon, and breast cancer from 2001-2003 and 2004-2009.
Site Logo
December 11th 2017

Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH

Surabhi Dangi-Garimella, PhD
Clonal hematopoiesis and selection pressures associated with aging can together lead to the development of neoplasms. Two hematologists presented US and European updates on the potential to develop a predictive model, and an appropriate intervention, in these individuals.
Site Logo
December 11th 2017

CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma

Jaime Rosenberg
Two abstracts at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia found that CTL019 shows promising potential in providing significant benefit and cost effectiveness for pediatric and young adult patients with B-cell acute lymphoblastic leukemia in both the United States and the United Kingdom.
Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines
December 10th 2017

Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines

Physician belief in the art of medicine is running up against the challenge of costs being shifted to patients and health systems and the desire of payers to have less variation in care, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.
Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response
December 10th 2017

Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response

Ibrutinib has the potential to improve vaccine response for patients with chronic lymphocytic leukemia, and an ongoing trial will help provide a better understanding, explained Kerry Rogers, MD, assistant professor, internal medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center.
Site Logo
December 10th 2017

Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being

Surabhi Dangi-Garimella, PhD
Three studies presented at the ongoing 59th Annual Meeting and Exposition of the American Society of Hematology in Atlanta, Georgia, shared progress on the oral Bruton’s tyrosine kinase inhibitor, ibrutinib, in the treatment of relapsed/refractory mantle cell lymphoma (MCL) and as a single agent in chronic lymphocytic leukemia (CLL).
Site Logo
December 10th 2017

Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care

Surabhi Dangi-Garimella, PhD
During a session on the first day of the 59th Annual Meeting and Exposition of the American Society of Hematology in Atlanta, Georgia, physicians shared current knowledge on cardiovascular toxicities of tyrosine kinase inhibitors (TKIs) as well as the potential for treatment-free remission with these agents.
UC San Diego Researchers Receive $600,000 Grant to Test PI3Ky Inhibitor
December 9th 2017

UC San Diego Researchers Receive $600,000 Grant to Test PI3Ky Inhibitor

Kelly Davio
A University of California San Diego School of Medicine and Moores Cancer Center research team studying new drugs that could break resistance to cancer immunotherapy has received a 3-year, $600,000 translational grant from the V Foundation for Cancer Research.
This Week in Managed Care: December 8, 2017
December 8th 2017

This Week in Managed Care: December 8, 2017

This week, the top managed care stories included CVS' proposal to purchase Aetna, which could reshape healthcare; a new study that looks at who is dying in hospitals from opioid use; and CMS reported that healthcare spending grew more slowly in 2016.
Ribociclib Plus Oral Endocrine Partner Shows Efficacy in Women With HR+/HER2- Breast Cancer
December 8th 2017

Ribociclib Plus Oral Endocrine Partner Shows Efficacy in Women With HR+/HER2- Breast Cancer

Jaime Rosenberg
Novartis announced that Phase III MONALEESA-7 trial results showed that the combination of ribociclib with an endocrine therapy (tamoxifen or an aromatase inhibitor) and goserelin yielded significant progression-free survival when compared with endocrine therapy and goserelin alone.
How Physicians Handle Differing Guidelines on Breast Cancer Screening Recommendations
December 6th 2017

How Physicians Handle Differing Guidelines on Breast Cancer Screening Recommendations

Laura Joszt, MA
WIth different societies and organizations releasing contrary guidelines around breast cancer screening, experience with past patients or friends and family members could influence physicians' decisions around when to start screening mammography.
Site Logo
December 6th 2017

Having Cancer Saved My Life

Samantha Eisenstein Watson, MBA
A Samfund grant recipient narrates her experience of being diagnosed young with cancer and how the support from The Samfund "made everyday school and life manageable."
Scientists Discover Gene That May Cause Melanoma to Metastasize
December 6th 2017

Scientists Discover Gene That May Cause Melanoma to Metastasize

Samantha DiGrande
A new study published Monday by scientists at the University of Massachusetts Medical School (UMMS) in Boston reports findings on a gene that is responsible for creating a protein that may help melanoma to grow and metastasize.
Systematic Review Finds Elevated Reporting for Thromboembolic Events With JAK Inhibitors
December 5th 2017

Systematic Review Finds Elevated Reporting for Thromboembolic Events With JAK Inhibitors

Kelly Davio
A systematic review of the FDA’s Adverse Event Reporting System (FAERS) found elevated reporting for both tofacitinib (Xeljanz) and ruxolitinib (Jakafi) for thromboembolic adverse events (AEs), suggesting the possibility of a class-wide issue with Janus kinase (JAK) inhibitors.
Site Logo
December 5th 2017

Majority of Patients Go Online for Information Following Cancer Diagnosis, Study Finds

Jaime Rosenberg
Health information brand Healthline launched its “State of…” series with its “State of Cancer” study, analyzing how digital information influences patient treatment decisions and recognizing generational differences.
First-of-a-Kind Companion Test for Cancer Gene Profiling Gets FDA Approval
December 5th 2017

First-of-a-Kind Companion Test for Cancer Gene Profiling Gets FDA Approval

Jaime Rosenberg
The FDA has approved Foundation Medicine's FoundationOne CDx, the first-of-a-kind comprehensive companion diagnostic test for solid tumors. The test looks for hundreds of cancer genes, providing healthcare professionals with a more complete picture of what's causing tumor growth and guidance for treatment decisions.
Site Logo
December 5th 2017

Study Compares Survival for Cancer, Based on Health Insurance Status

Samantha DiGrande
A study published Thursday in JAMA Oncology found that improvements in survival among California cancer patients were almost exclusively limited to patients with private or Medicare insurance.
Site Logo
December 1st 2017

The Importance of Teamwork in Oncology Care Transitions

Surabhi Dangi-Garimella, PhD
A panel on the importance of clinical and non-clinical stakeholders in a patient’s care trajectory brought together a diverse group of stakeholders at The American Journal of Managed Care®’s Patient-Centered Oncology Care® meeting.
Diabetes, High BMI Account for Nearly 800,000 New Cancer Cases Worldwide
November 30th 2017

Diabetes, High BMI Account for Nearly 800,000 New Cancer Cases Worldwide

Mary Caffrey
Liver and endometrial cancer accounted for high numbers of new cases; increases of these cancer types have been attributed to rising rates of diabetes and obesity.
Shawnee Mission Health Partners With Top-Ranked Cancer Network to Deliver World-Class Cancer Care Locally
November 30th 2017

Shawnee Mission Health Partners With Top-Ranked Cancer Network to Deliver World-Class Cancer Care Locally

Jaime Rosenberg
After a year-long process, Shawnee Mission Health (SMH) is now a certified member of the MD Anderson Cancer Network, the top ranked cancer center in the US. The 2 will work together to raise the standard of cancer care in the Kansas City metropolitan community through patient-centered care.
<1
...
616263646566676869
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo